Page 1 of 4, showing 50 records out of 165 total, starting on record 1, ending on 50
| Publication |
Category |
Year |
|
1. Bydal, P., Luu-The, V., Labrie, F., Poirier, D. (2009) Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem.44:632-644. |
DHEA |
2009 |
|
2. Labrie, F. (2008) Preface. Best Pract Res Clin Endocrinol Metab, 22: pp. vii-ix. |
DHEA |
2008 |
|
10. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. |
DHEA |
2007 |
|
11. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. |
DHEA |
2007 |
|
14. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. |
DHEA |
2007 |
|
16. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
DHEA |
2006 |
|
19. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. |
DHEA |
2005 |
|
20. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. |
DHEA |
2005 |
|
21. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. |
DHEA |
2004 |
|
22. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. |
DHEA |
2004 |
|
23. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. |
DHEA |
2004 |
|
25. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. |
DHEA |
2004 |
|
28. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17beta-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. |
DHEA |
2004 |
|
30. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. |
DHEA |
2003 |
|
31. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. |
DHEA |
2003 |
|
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
DHEA |
2002 |
|
40. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
DHEA |
2001 |
|
51. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. |
DHEA |
2000 |
|
56. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. |
DHEA |
1999 |
|
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
DHEA |
1999 |
|
77. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. |
DHEA |
1998 |
|
96. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. |
DHEA |
1996 |
|
98. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. |
DHEA |
1996 |
|
104. Labrie, F., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (1996) Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology, in First International Consultation on Prostate Cancer, Monaco, pp Published on CD-ROM. |
DHEA |
1996 |
|
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. |
DHEA |
1995 |
|
121. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Labrie, F. (1994) Changes in serum concentration of conjugated and unconjugated steroids in 40- to 80-year old men. J. Clin. Endocrinol. Metab., 79: 1086-1090. |
DHEA |
1994 |
|
124. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. |
DHEA |
1994 |
|
129. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. |
DHEA |
1994 |
|
135. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. |
DHEA |
1993 |
|
139. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. |
DHEA |
1993 |
|
160. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. |
DHEA |
1991 |
|
167. Labrie, C., Simard, J., Poulin, M., Bélanger, A., Pelletier, G., Labrie, F. (1990) Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 392-394. |
DHEA |
1990 |
|
168. Labrie, C., Simard, J., Zhao, H.F., Bélanger, A., Pelletier, G., Labrie, F. (1990) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 395-398. |
DHEA |
1990 |
|
178. Bélanger, B., Bélanger, A., Labrie, F., Dupont, A., Cusan, L., Monfette, G. (1989) Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem., 32: 695-698. |
DHEA |
1989 |
|
181. Labrie, C., Simard, J., Marchetti, B., Pelletier, G., Zhao, H.F., Bélanger, A., Labrie, F. (1989) Conversion of precursor adrenal steroids into potent androgens in peripheral tissue, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 1-22. |
DHEA |
1989 |
|
182. Labrie, C., Simard, J., Zhao, H., Bélanger, A., Pelletier, G., Labrie, F. (1989) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 124: 2745-2754. |
DHEA |
1989 |
|
199. Bégin, D., Luthy, I.A., Labrie, F. (1988) Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol. Cell. Endocrinol., 58: 213-219. |
DHEA |
1988 |
|
205. Labrie, C., Bélanger, A., Labrie, F. (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123: 1412-1417. |
DHEA |
1988 |
|
280. Bélanger, A., Dupont, A., Labrie, F. (1984) Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422-426. |
DHEA |
1984 |
|
353. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2009) Effect of One-Week Treatment with Vaginal Estrogen Preparations on Serum Estrogen Levels in Postmenopausal Women. Menopause, 16: 30-36. |
DHEA |
2009 |
|
355. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. |
DHEA |
2007 |
|
356. Luu-The, V., Ferraris, C., Duche, D., Bélanger, P., Leclaire, J., Labrie, F. (2007) Steroid metabolism and profile of steroidogenic gene expression in EpiskinTM: High similarity with human epidermis. J Steroid Biochem Mol Biol 107: 30-36. |
DHEA |
2007 |
|
358. Berger, L., El-Alfy, M., Martel, C., Labrie, F. (2005) Effects of DHEA, Premarin and Acolbifene on histomorphology and sex steroid receptors of the rat vagina. J Steroid Biochem Mol Biol, 96: 201-15. |
DHEA |
2005 |
|
360. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. |
DHEA |
2000 |
|
363. Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Labrie, F. (1996) Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J. Endocrinol., 150 Suppl.: S43-S50. |
DHEA |
1996 |
|
373. Berger, L., El-Alfy, M., Labrie, F. (2008) Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. J Steroid Biochem Mol Biol, 109: 67-80. |
DHEA |
2008 |
|
374. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. |
DHEA |
2008 |
|
376. Pelletier, G., Labrie, C., Martel, C., Labrie, F. (2008) Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology. J Steroid Biochem Mol Biol, 108: 102-108. |
DHEA |
2008 |
|
379. Liu, H., Zheng, S.F., Bellemare, V., Pelletier, G., Labrie, F., Luu-The, V. (2007) Expression and localization of estrogenic type 12 17beta-hydroxysteroid dehydrogenase in the cynomolgus monkey. BMC Biochem, 8: 2 |
DHEA |
2007 |
|
380. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. |
DHEA |
2006 |